Pathological assessment of the lymph node biopsies for lymphadenopathy in rheumatoid arthritis.
Pathological assessment of the lymph node biopsies for lymphadenopathy in rheumatoid arthritis.
复制标题
类风湿性关节炎淋巴结病淋巴结活检的病理学评估。
DOI:
10.1080/14397595.2019.1675260
复制
发表时间:
2020
期刊:
影响因子:
--
通讯作者:
12th)
中科院分区:
文献类型:
--
作者:
Yamada C;Hoshida Y;et al. (12;12th)
Objectives:To assess the incidence of reactive lymph node hyperplasia (RLH) and the diagnostic characteristics that can help differentiate it from lymphoproliferative disorders (LPD) in patients with rheumatoid arthritis (RA).Methods:Data on patient characteristic from 32 consecutive RA patients with lymphadenopathy at a single medical center over a 6-year period were collected and analyzed to determine whether any of these characteristics can differentiated RLH from LPD.Results:LPD including methotrexate (MTX) - associated LPD (MTX-LPD) and RLH were diagnosed in 19 and 10 patients, respectively. Conclusive diagnosis was not reached in the remaining three cases and they were regarded as grey-zone cases. Age, levels of lactate dehydrogenase (LDH) and soluble interleukin-2 receptor (sIL-2R), as well as maximum standardized uptake value (SUVmax), were significantly higher in LPD than in RLH patients. The diagnosis cut-off values for these parameters were 66 year, 169 U/L, 899 U/mL and 8.18, respectively, based on the receiver operating characteristics curve analysis for both RLH and LPD.Conclusions:About one-third of patients with RA who presented with lymphadenopathy had reactive lymph node enlargement. Older age and higher levels of LDH, sIL-2R, and SUVmaxare more associated with LPD than should be considered when deciding to perform a biopsy.